ER-Positive HER2-Negative Breast Cancer
Conditions
Keywords
Metastatic, Breast Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Next Generation Oral SERD, Antineoplastic Agents, Estrogen Receptor Antagonists, Camizestrant
Brief summary
The purpose of this study is to investigate the efficacy, safety, and tolerability of camizestrant in combination with ribociclib in patients with ER+ HER2- BC who have not received any other systemic treatment for advanced disease. Participants will be treated within the trial until they discontinue the study treatment for any reason.
Detailed description
This global, multicenter, Phase IIIb, single-arm study will evaluate the efficacy, safety, and tolerability of camizestrant combined with ribociclib in patients with ER+ HER2- advanced breast cancer who have not previously received systemic therapy for advanced disease. Approximately 150 participants will be enrolled, and all enrolled participants will receive standard daily oral doses of camizestrant 75 mg and ribociclib 600 mg until treatment discontinuation.
Interventions
DRUGCamizestrant
Patients will receive the standard dose of camizestrant once daily as oral tablets
DRUGRibociclib
Patients will receive the standard dose of ribociclib once daily as oral tablets
Sponsors
AstraZeneca
ICON plc
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Interventional, prospective, single-arm, open-label study
Eligibility
Sex/Gender
ALL
Age
18 Years to 130 Years
Healthy volunteers
No
Inclusion criteria
1. Capable of giving signed informed consent. 2. Female or male, must be ≥ 18 years or as per locally allowed age limit for screening. Type of Participant and Disease Characteristics 3. Histologically or cytologically documented diagnosis of ER+, HER2- BC based on local laboratory results and who are not amenable to resection or radiation therapy with curative intent. 4. Previously untreated with any systemic anti-cancer therapy for their locoregionally recurrent or metastatic ER+ disease. 5. De novo Stage 4 disease, or recurrence from early CD stage breast cancer after having received standard adjuvant endocrine therapy. Note that at least 12 months must have elapsed since the patient's last dose of adjuvant AI therapy without disease progression on treatment. Note that a 2-week washout period is required after the last dose of tamoxifen prior to randomisation. 6. ECOG performance status of 0 or 1. 7. Adequate organ and marrow function. Sex and Contraceptive/Barrier Requirements 8. For those female or male patients who are not abstinent (in line with their preferred and usual lifestyle choice), and intend to be heterosexually active with a partner: Female patients must be using highly effective contraceptive measures from the time of screening until 4 weeks after discontinuation of study treatment, and must have a negative serum pregnancy test before first dose of any study treatment if they are of childbearing potential; or must have evidence of nonchild-bearing potential by fulfilling one of the following criteria at screening: (a) Post-menopausal, defined as women with cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause: (i) Age ≥ 60 years (ii) Age \< 60 years with serum estradiol and FSH level within the laboratory's reference range for post-menopausal females (iii) Previous bilateral surgical oophorectomy (iv) Medically confirmed ovarian failure OR (b) Pre/peri-menopausal, ie, not meeting the criteria for being post-menopausal. (i) Pre-/peri-menopausal women can be enrolled if amenable to be treated with monthly LHRH agonists (goserelin or leuprorelin \[also known as leuprolide\]). Patients must have concomitant treatment with LHRH agonists (goserelin or leuprorelin \[leuprolide\]) before or on the same day as the first dose of study treatment - and must be willing to continue on it for the duration of the study. Non sterilised male partners of a patient who is a woman of childbearing potential must use a male condom plus spermicide (condom alone in countries where spermicides are not approved) throughout this period. Male participants who intend to be sexually active with a female partner of childbearing potential must be surgically sterile or using an acceptable method of contraception from the time of screening throughout the total duration of the programme and the drug washout period to prevent pregnancy in a partner. Male participants must not donate or bank sperm during this same time period. Male patients can be enrolled if amenable to be treated with monthly LHRH agonists (goserelin or leuprorelin \[also known as leuprolide\]) unless the patients have clear orchiectomy medical history. Willingness to use 2 non-hormonal based methods of contraception throughout the study.
Exclusion criteria
1. Participants who are not clinically indicated for endocrine therapy in combination with the CDK4/6 inhibitor ribociclib. 2. No evidence of advanced inoperable disease, or bone only disease with sclerotic/osteoblastic bone lesions only per standard of care imaging. 3. Have advanced, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term, and/or pulmonary lymphangitis. 4. Persistent treatment-induced non-haematological toxicities (CTCAE Grade \> 2). 5. Known active infection including tuberculosis HBV and HCV. 6. Known to have tested positive for HIV. Participants with HIV may be enrolled if they fulfil the criteria recommended by FDA and ASCO guidelines. 7. Any clinically important abnormalities in heart conduction patterns; participants with pacemakers or medically controlled atrial fibrillation are not excluded. 8. Ongoing symptomatic hypotension. 9. Pregnant or lactating women or patients not willing to use highly effective contraception as defined in the protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of camizestrant and ribociclib by time to next treatment (TTNT) | Following first dose of study treatment until earliest of subsequent therapy, death and 2 years after first dose of study treatment. | TTNT is defined as time from the date of the first administration of study treatment to the earliest start date of subsequent anti-cancer medication or death. The primary measure of interest is the TTNT event-free rate at 2 years. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CTCAE grade ≥ 3 associated with camizestrant and ribociclib within first 6 months of study treatment | Following first dose of study treatment until 6 months later | Incidence of Grade \>=3 CTCAEs associated with Camizestrant and/or Ribo within first 6 months of receiving study treatment. |
| Efficacy of camizestrant and ribociclib by time to discontinuation (TTD) | Following first dose of study treatment until earliest of discontinuation of camizestrant, death and 2 years after first dose of study treatment | TTD is defined as time from the date of the first administration of study treatment to the earliest date of camizestrant treatment discontinuation or death. The primary measure of interest is the TTD event-free rate at 2 years. |
| Efficacy of camizestrant and ribociclib by progression free survival (PFS) | Following first dose of study treatment until earliest of death, disease progression, and 2 years after first dose of study treatment. | PFS is defined as time from first dose of study treatment until progression per RECIST 1.1 as assessed by investigator or death due to any cause. The primary measures of interest are the PFS event-free rates at 1 and 2 years. |
Countries
France, Germany, Italy, Poland, South Korea, Spain, Switzerland, United Arab Emirates, United States
Contacts
CONTACTAstraZeneca Clinical Study Information Center
Outcome results
None listed